Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by National Bank of Canada FI

National Bank of Canada FI increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 196.5% in the third quarter, HoldingsChannel.com reports. The firm owned 190,912 shares of the medical equipment provider’s stock after acquiring an additional 126,528 shares during the quarter. National Bank of Canada FI’s holdings in Hologic were worth $15,551,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of HOLX. EP Wealth Advisors LLC acquired a new position in Hologic in the third quarter valued at approximately $811,000. Insigneo Advisory Services LLC acquired a new position in shares of Hologic in the 3rd quarter valued at $457,000. Worldquant Millennium Advisors LLC grew its position in shares of Hologic by 200.0% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 184,170 shares of the medical equipment provider’s stock valued at $15,002,000 after buying an additional 122,784 shares during the last quarter. Wahed Invest LLC raised its stake in Hologic by 8.3% during the 3rd quarter. Wahed Invest LLC now owns 5,551 shares of the medical equipment provider’s stock worth $452,000 after acquiring an additional 424 shares in the last quarter. Finally, Weiss Asset Management LP purchased a new stake in Hologic in the third quarter valued at $15,291,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $76.83 on Wednesday. Hologic, Inc. has a 52 week low of $68.15 and a 52 week high of $84.67. The company has a 50-day moving average price of $79.62 and a 200 day moving average price of $78.60. The company has a market cap of $17.44 billion, a P/E ratio of 23.07, a PEG ratio of 2.37 and a beta of 0.96. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period last year, the firm earned $0.89 EPS. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HOLX. Raymond James lifted their target price on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Leerink Partners reduced their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Evercore ISI raised their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Royal Bank of Canada upped their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Finally, UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.50.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.